{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+matching+risperidone", "query": { "intervention": "Placebo matching risperidone" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 18, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+matching+risperidone&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T16:10:21.128Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03055338", "title": "An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia, Acute Episode" ], "interventions": [ { "name": "Elpipodect", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo matching MK-8189", "type": "DRUG" }, { "name": "Placebo matching risperidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 224, "start_date": "2017-03-08", "completion_date": "2018-01-09", "has_results": true, "last_update_posted_date": "2026-04-29", "last_synced_at": "2026-09-27T16:10:21.128Z", "location_count": 28, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Bellflower", "state": "California" }, { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03055338" }, { "nct_id": "NCT00158028", "title": "Risperidone in the Treatment of Psychotic-like and Deficit Symptoms of Schizotypal Personality Disorder", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Schizotypal Personality Disorder" ], "interventions": [ { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 25, "start_date": "1995-11", "completion_date": "2001-12", "has_results": false, "last_update_posted_date": "2016-08-04", "last_synced_at": "2026-09-27T16:10:21.128Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00158028" }, { "nct_id": "NCT03893825", "title": "A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "TV-46000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "13 Years to 65 Years" }, "enrollment_count": 336, "start_date": "2019-04-17", "completion_date": "2021-12-02", "has_results": true, "last_update_posted_date": "2022-12-07", "last_synced_at": "2026-09-27T16:10:21.128Z", "location_count": 67, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03893825" }, { "nct_id": "NCT04567524", "title": "A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia Schizoaffective" ], "interventions": [ { "name": "LYN-005", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lyndra Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 34, "start_date": "2020-08-13", "completion_date": "2020-12-22", "has_results": true, "last_update_posted_date": "2023-02-08", "last_synced_at": "2026-09-27T16:10:21.128Z", "location_count": 5, "location_summary": "Long Beach, California • Atlanta, Georgia • Marlton, New Jersey + 2 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Marlton", "state": "New Jersey" }, { "city": "Austin", "state": "Texas" }, { "city": "Richardson", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04567524" }, { "nct_id": "NCT02469155", "title": "A Trial to Assess the Antipsychotic Efficacy of ITI-007 Over 6 Weeks of Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "ITI-007", "type": "DRUG" }, { "name": "Risperidone", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Intra-Cellular Therapies, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 696, "start_date": "2015-06", "completion_date": "2016-08", "has_results": true, "last_update_posted_date": "2025-10-02", "last_synced_at": "2026-09-27T16:10:21.128Z", "location_count": 11, "location_summary": "Little Rock, Arkansas • Springdale, Arkansas • Culver City, California + 8 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Springdale", "state": "Arkansas" }, { "city": "Culver City", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02469155" }, { "nct_id": "NCT03557931", "title": "A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "ASP4345", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" }, { "name": "quetiapine", "type": "DRUG" }, { "name": "olanzapine", "type": "DRUG" }, { "name": "ziprasidone", "type": "DRUG" }, { "name": "aripiprazole", "type": "DRUG" }, { "name": "brexpiprazole", "type": "DRUG" }, { "name": "paliperidone", "type": "DRUG" }, { "name": "lurasidone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 233, "start_date": "2018-07-13", "completion_date": "2019-10-21", "has_results": true, "last_update_posted_date": "2024-11-12", "last_synced_at": "2026-09-27T16:10:21.128Z", "location_count": 27, "location_summary": "Cerritos, California • Garden Grove, California • Lemon Grove, California + 19 more", "locations": [ { "city": "Cerritos", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Lemon Grove", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Pico Rivera", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03557931" }, { "nct_id": "NCT02202213", "title": "Safety and Tolerability Study of Lu AF11167 After Repeated Dosing in Patients With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Lu AF11167", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lundbeck A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 47, "start_date": "2013-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-02-18", "last_synced_at": "2026-09-27T16:10:21.128Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02202213" }, { "nct_id": "NCT00509067", "title": "Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "Galantamine", "type": "DRUG" }, { "name": "CDP-choline", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 43, "start_date": "2007-11", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2018-04-11", "last_synced_at": "2026-09-27T16:10:21.128Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00509067" }, { "nct_id": "NCT03503318", "title": "Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "TV-46000", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "13 Years to 65 Years" }, "enrollment_count": 544, "start_date": "2018-04-27", "completion_date": "2020-12-03", "has_results": true, "last_update_posted_date": "2023-03-10", "last_synced_at": "2026-09-27T16:10:21.128Z", "location_count": 73, "location_summary": "Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 58 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Bellflower", "state": "California" }, { "city": "Colton", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03503318" }, { "nct_id": "NCT00563706", "title": "Study Evaluating Vabicaserin in Subjects With Schizophrenia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Schizophrenia" ], "interventions": [ { "name": "vabicaserin", "type": "DRUG" }, { "name": "risperidone", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 199, "start_date": "2007-12", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2014-03-20", "last_synced_at": "2026-09-27T16:10:21.128Z", "location_count": 32, "location_summary": "Little Rock, Arkansas • Cerritos, California • Escondido, California + 27 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Cerritos", "state": "California" }, { "city": "Escondido", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00563706" } ] }